Skip to content

Study · Animal study (in vivo) · mouse · 2011

5 results

IGF-1 has plaque-stabilizing effects in atherosclerosis by altering vascular smooth muscle cell phenotype.

von der Thüsen JH, Borensztajn KS, Moimas S, van Heiningen S, Teeling P, van Berkel TJ, Biessen EA

The American journal of pathology1 Feb 2011Cited by 75 (Europe PMC)

PMID21281823 (opens in a new tab)PMCIDPMC3069834 (opens in a new tab)DOI10.1016/j.ajpath.2010.10.007 (opens in a new tab)PepBankPUB-21281823
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In apolipoprotein E knockout mice, Long R3 IGF-1 reduced stenosis in early atherosclerosis.

    In plain wordsIn mice with early plaque buildup, Long R3 IGF-1 reduced narrowing of the artery.

    Peptide
    IGF-1 LR3
    Outcome
    DecreaseStenosis in early atherosclerosis
    Study

    mousen: not reported in source

    apolipoprotein E knockout mice
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vivo, treatment with the stable IGF-1 analog Long R3 IGF-1 in apolipoprotein E knockout mice reduced stenosis and core size, and doubled cap/core ratio in early atherosclerosis.
    1 context sentence
    Summary · context
    To investigate this hypothesis, we studied the effects of the highly inflammatory milieu of the atherosclerotic plaque on IGF-1 signaling and stability-related phenotypic parameters of murine vSMCs in vitro, and the effects of IGF-1 supplementation on plaque phenotype in an atherosclerotic mouse model.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In apolipoprotein E knockout mice, Long R3 IGF-1 reduced plaque core size in early atherosclerosis.

    In plain wordsIn mice with early plaque buildup, Long R3 IGF-1 reduced the size of the plaque core.

    Peptide
    IGF-1 LR3
    Outcome
    DecreasePlaque core size in early atherosclerosis
    Study

    mousen: not reported in source

    apolipoprotein E knockout mice
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vivo, treatment with the stable IGF-1 analog Long R3 IGF-1 in apolipoprotein E knockout mice reduced stenosis and core size, and doubled cap/core ratio in early atherosclerosis.
    1 context sentence
    Summary · context
    To investigate this hypothesis, we studied the effects of the highly inflammatory milieu of the atherosclerotic plaque on IGF-1 signaling and stability-related phenotypic parameters of murine vSMCs in vitro, and the effects of IGF-1 supplementation on plaque phenotype in an atherosclerotic mouse model.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In apolipoprotein E knockout mice, Long R3 IGF-1 doubled the cap/core ratio in early atherosclerosis.

    In plain wordsIn mice with early plaque buildup, Long R3 IGF-1 doubled the ratio of plaque cap to core.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseCap/core ratio in early atherosclerosis
    Study

    mousen: not reported in source

    apolipoprotein E knockout mice
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In vivo, treatment with the stable IGF-1 analog Long R3 IGF-1 in apolipoprotein E knockout mice reduced stenosis and core size, and doubled cap/core ratio in early atherosclerosis.
    1 context sentence
    Summary · context
    To investigate this hypothesis, we studied the effects of the highly inflammatory milieu of the atherosclerotic plaque on IGF-1 signaling and stability-related phenotypic parameters of murine vSMCs in vitro, and the effects of IGF-1 supplementation on plaque phenotype in an atherosclerotic mouse model.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In apolipoprotein E knockout mice with advanced plaques, Long R3 IGF-1 increased plaque vSMC content by more than twofold.

    In plain wordsIn mice with advanced plaques, Long R3 IGF-1 more than doubled the smooth muscle cell content of the plaque.

    Peptide
    IGF-1 LR3
    Outcome
    IncreaseVascular smooth muscle cell content of advanced plaques
    Study

    mousen: not reported in source

    apolipoprotein E knockout mice
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In advanced plaques, Long R3 IGF-1 increased the vSMC content of the plaque by more than twofold and significantly reduced the rate of intraplaque hemorrhage.
    1 context sentence
    Summary · context
    To investigate this hypothesis, we studied the effects of the highly inflammatory milieu of the atherosclerotic plaque on IGF-1 signaling and stability-related phenotypic parameters of murine vSMCs in vitro, and the effects of IGF-1 supplementation on plaque phenotype in an atherosclerotic mouse model.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In apolipoprotein E knockout mice with advanced plaques, Long R3 IGF-1 significantly reduced the rate of intraplaque hemorrhage.

    In plain wordsIn mice with advanced plaques, Long R3 IGF-1 reduced bleeding inside the plaque.

    Peptide
    IGF-1 LR3
    Outcome
    DecreaseIntraplaque hemorrhage rate in advanced plaques
    Study

    mousen: not reported in source

    apolipoprotein E knockout mice
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In advanced plaques, Long R3 IGF-1 increased the vSMC content of the plaque by more than twofold and significantly reduced the rate of intraplaque hemorrhage.
    1 context sentence
    Summary · context
    To investigate this hypothesis, we studied the effects of the highly inflammatory milieu of the atherosclerotic plaque on IGF-1 signaling and stability-related phenotypic parameters of murine vSMCs in vitro, and the effects of IGF-1 supplementation on plaque phenotype in an atherosclerotic mouse model.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.